他达拉非治疗继发于良性前列腺增生下尿路症状的研究进展

Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia

他达拉非作为新一代的选择性磷酸二酯酶-5抑制剂(PDE5Is)为男性勃起功能障碍(ED)的治疗带来了全新的理念。继发于男性良性前列腺增生症(BPH)的下尿路症状(LUTS)由于其病因的复杂性,治疗效果受到多因素的影响,使得传统的临床治疗方法不可避免地存在各种难以预测的并发症。目前日益受到关注的他达拉非每日一次口服方案(OAD)治疗ED的新方案在临床研究中表现出了对继发于BPH的LUTS的显著的疗效,在治疗的早期,国际前列腺症状评分(IPSS)就得以显著改善。还有研究表明在同时存在ED和LUTS症状的BPH患者中,他达拉非也显著有效。本文旨在回顾PDE5Is对BPH相关症状治疗的相关研究进展,综述他达拉非治疗继发于BPH的LUTS的有效性和安全性证据。

Tadalafil, as a selective phosphodiesterase type 5 inhibitor （ PDE5 I）, has revolutionized the treatment of erectile dys- function （ED） in men. Conventional management of lower urinary tract symptoms （LUTS） secondary to benign prostatic hyperplasia （ BPH）, which is highly complex and likely muhifactorial, is associated with unwanted side effects. Innovative once-daily tadalafil reg- imen is effective in treating the signs and symptoms of BPH. In recent trials in men with BPH, tadalafil significantly improved total IP- SS over the initial 12 weeks of medication. Moreover, tadalafil is effective in treating both ED and the signs and symptoms of BPH. In this study, we review the current state of this new management strategy for LUTS secondary to BPH, highlighting the published reports on the efficacy and tolerability of tadalafil .